PSTX - Poseida Therapeutics GAAP EPS of $0.92 beats by $1.57 revenue of $116.3M beats by $115.47M November, 10 2022 05:15 PM Poseida Therapeutics Inc. Poseida Therapeutics press release ( NASDAQ: PSTX ): Q3 GAAP EPS of $0.92 beats by $1.57 . Revenue of $116.3M beats by $115.47M . For further details see: Poseida Therapeutics GAAP EPS of $0.92 beats by $1.57, revenue of $116.3M beats by $115.47M